SecBot SecBot
8-K ·Filed Sep 11, 2026

ARTV

Artiva Biotherapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed2mo ago SEC0001193125-26-389308
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for future equity award grants under the expanded plan, which could signal management's confidence or need for retention incentives. The 10.4% potential dilution is notable for a biotech with a ~$509M market cap, but is standard for a pre-commercial stage company. No immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$10.14
T+0 close · Sep 11, 2026 · via day close
Latest settled
−33.23%
T+20 · $6.77 · next T+60 in 21d
Vs SPY
−35.50%
α at T+20
Latest observation
−53.11%
T+45 · FF3 residual α
  1. T+0 · Sep 14 $10.14entry
  2. T+1 · 2mo ago −12.13%α −11.67% · $8.91
  3. T+5 · 8w ago −22.78%α −24.44% · $7.83
  4. T+20 · 5w ago −33.23%α −35.50% · $6.77
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Artiva Biotherapeutics held its 2026 Annual Meeting on September 8, 2026, where stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the share reserve by 5,097,095 shares and modifying the annual automatic increase calculation to include pre-funded warrant shares. The meeting also saw the re-election of Class II directors Brian Daniels and Laura Stoppel, and the ratification of KPMG as auditor. This is a routine governance filing with no material financial impact.

Key Facts

  • Stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing authorized shares by 5,097,095 shares.
  • The amendment also modifies the annual automatic share reserve increase calculation to include shares issuable upon exercise of pre-funded warrants.
  • Class II directors Brian Daniels, M.D. and Laura Stoppel, Ph.D. were re-elected to three-year terms.
  • KPMG LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
  • The total share reserve under the amended plan is 13,328,057 shares.
  • As of the record date (July 20, 2026), 48,885,777 shares of common stock were outstanding.

Financial Impact

No direct financial impact. The equity plan amendment increases potential dilution by up to 5,097,095 shares (approximately 10.4% of shares outstanding as of the record date), but shares are issued only upon future award grants and vesting.

dilution

Risk Factors

  • Potential dilution from future equity awards under the expanded plan.
  • No financial results or guidance were provided in this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-389308
Document: artv-20260908.htm0001193125-26-389308
Document: 0001193125-26-389308-index-headers.html0001193125-26-389308
Document: 0001193125-26-389308-index.html0001193125-26-389308
Document: 0001193125-26-389308.txt0001193125-26-389308

Track record

33 reports on ARTV

Performance horizon

11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Viewing Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 7h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 11, 2026